Oxidized lipids and UV immunosuppression
Oxidized lipids and UV immunosuppression
批准号:
8196344
负责人:
Jeffrey B. Travers
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-10-01 至 2015-09-30
关键词:
Actinic keratosisAgonistAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsCancerousCellsChronicClinicalComplexContact hypersensitivityDiseaseEicosanoidsEnvironmental Risk FactorEnzymesExposure toFree RadicalsGoalsHealthcareHistamineHumanImmunosuppressionImmunosuppressive AgentsIn VitroInflammatoryInterleukin-10LaboratoriesLigandsLipidsMass Spectrum AnalysisMediatingMediator of activation proteinModelingMorbidity - disease rateMusMutagensNeoplasmsPathway interactionsPhototherapyPlatelet Activating FactorPlayProcessProductionPropertyRadiationReactive Oxygen SpeciesRegulatory T-LymphocyteResearchResourcesRoleSkinSkin CancerSkin CarcinomaStimulusSun ExposureSunlightTestingTherapeutic EffectTransplantationUltraviolet B RadiationVeteranscell typecyclooxygenase 2cytokinedesignin vivoinsightkeratinocytemast cellmortalityneoplasticnoveloxidationoxidized lipidplatelet activating factor receptorpublic health relevanceresearch studyresponseskin disorderstressortoolultraviolet
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
PROJECT SUMMARY: The primary goal of our research is to mechanistically characterize systemic immunosuppression induced by ultraviolet B radiation (UVB). The immunosuppressive effects of UVB are involved in the ability of this environmental stimulus to induce skin cancers. Moreover, UVB radiation treatments are used clinically to treat inflammatory skin disorders, in great part to its immunosuppressive effects. The planned research plans to take advantage of results of previous studies both in our laboratory and others indicating that UVB-mediated systemic immunosuppression involves novel glycerophosphocholine-derived lipids produced by epidermal cells in response to UVB. These compounds, some of which have not been structurally characterized, act as agonists for the Platelet-activating Factor (PAF) receptor. Accumulating evidence suggests that these PAF-R agonists exert immunosuppressive effects via a complex interplay of cell types and cytokines including mast cells, cyclooxygenase-2-produced eicosanoids, interleukin-10 and histamine. Two specific aims are planned to mechanistically characterize the complex pathway of UVB-mediated systemic immunosuppression using a well-established murine model of contact hypersensitivity. The first aim will use mass spectrometry to structurally characterize and quantitate PAF-R agonists produced by UVB in murine skin. The amounts of these novel PAF-R ligands produced enzymatically as well as through non- enzymatic free radical-mediated oxidation of glycerophosphosphocholines will be assessed using a mouse defective in PAF enzymatic synthesis and use of systemic antioxidants. The second aim will characterize the roles of mast cells and regulatory T cells using novel murine transplantation studies. Completion of the planned studies to characterize the cell types and mediators involved in UVB-mediated systemic immunosuppression should result in an enhanced understanding of this important process intimately involved in skin cancer.
PUBLIC HEALTH RELEVANCE:
PROJECT NARRATIVE: The primary goal of our research is to mechanistically characterize the cell types and mediators involved in ultraviolet B radiation (UVB)-mediated systemic immunosuppression. The immunosuppressive effects of UVB are involved in the ability of this environmental stimulus to induce skin cancers. These skin cancers and pre- cancerous actinic keratoses induced by chronic sun exposure are the most common form of neoplastic disorders found in veterans. Though usually not associated with increased mortality, actinic neoplasias constitute an enormous burden of health care resources and increased morbidity. Moreover, UVB radiation treatments are used clinically to treat inflammatory skin disorders, in great part to its immunosuppressive effects. These studies should result in an enhanced understanding of this important process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
-
批准号:10595503
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Jeffrey B. Travers
-
依托单位:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
-
批准号:10295161
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Jeffrey B. Travers
-
依托单位:
Validation of Mesoscopic Imaging to Predict Cutaneous Carcinogenesis and its Therapeutic Response
-
批准号:10041690
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:8967172
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:8539867
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:8892803
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
IGF-1 and the initiation of non-melanoma skin cancer
-
批准号:9242476
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jeffrey B. Travers
-
依托单位:
The Indiana Cutaneous Biological Research Training Program
-
批准号:8473519
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2013
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8391609
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8762399
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:8597389
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized lipids and UV immunosuppression
-
批准号:7932683
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized Lipids and UV Immunosuppression
-
批准号:10293535
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized Lipids and UV Immunosuppression
-
批准号:10514568
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Oxidized Lipids and UV Immunosuppression
-
批准号:10010381
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Jeffrey B. Travers
-
依托单位:
Bacterial Products as Potentiaters of AD
-
批准号:7150325
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2006
-
负责人:Jeffrey B. Travers
-
依托单位:
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY
-
批准号:6537618
-
项目类别:
-
资助金额:$30.98万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
Platelet Activating Factor and Epidermal Cytoxicity
-
批准号:9883903
-
项目类别:
-
资助金额:$37.5万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
Platelet Activating Factor and Epidermal Cytoxicity
-
批准号:10531858
-
项目类别:
-
资助金额:$37.5万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
PLATELET ACTIVATING FACTOR AND EPIDERMAL CYTOTOXICITY
-
批准号:6184728
-
项目类别:
-
资助金额:$25.21万
-
财政年份:1999
-
负责人:Jeffrey B. Travers
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: